Oakwell Private Wealth Management LLC Increases Position in Novo Nordisk A/S (NYSE:NVO)

Oakwell Private Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,163 shares of the company’s stock after purchasing an additional 904 shares during the period. Oakwell Private Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $702,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Center for Financial Planning Inc. raised its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $42,000. Albion Financial Group UT increased its holdings in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 0.4 %

Shares of NVO stock opened at $90.94 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The company’s fifty day moving average price is $85.32 and its 200-day moving average price is $107.42. The company has a market capitalization of $408.07 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NVO shares. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.